<DOC>
	<DOCNO>NCT02923921</DOCNO>
	<brief_summary>To compare efficacy AM0010 combination FOLFOX versus FOLFOX alone patient metastatic pancreatic cancer measure overall survival</brief_summary>
	<brief_title>Study AM0010 With FOLFOX Compared FOLFOX Alone Second-line Tx Pts With Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>This open-label , multi-center , randomize , Phase 3 study design compare efficacy safety AM0010 combination FOLFOX versus FOLFOX alone patient metastatic adenocarcinoma pancreas progress one prior gemcitabine contain regimen .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>1 . The presence metastatic pancreatic adenocarcinoma 2 . Measurable disease per RECIST v.1.1 3 . Patient must document tumor progression follow gemcitabine contain regimen treat metastatic disease establish CT MRI scan 4 . Eastern Cooperative Oncology Group Performance Status 0 1 5 . Patient must complete prior chemotherapy least 2 week ( washout period ) prior randomization recover toxicity Grade 1 baseline 6 . Patients must receive previous radiation therapy investigational therapy treatment advance metastatic disease . 7 . Patients receive cytotoxic dos gemcitabine chemotherapy adjuvant set eligible study 8 . No peripheral neuropathy 9 . No known history dihydropyrimidine dehydrogenase deficiency 1 . Diagnosis pancreatic islet neoplasm , acinar cell carcinoma , non adenocarcinoma ( i.e. , lymphoma , sarcoma ) , adenocarcinoma originate biliary tree , cystadenocarcinoma 2 . Patient Coumadin willing change LMWH oral Factor II Xa inhibitor halflife le 24 hour . 3 . Patient receive prior treatment AM0010 fluoropyrimidine/platinum contain regimen 4 . Patients intolerant gemcitabine contain regimen . 5 . History positivity human immunodeficiency virus 6 . Chronic active active viral hepatitis A , B , C infection 7 . Clinically significant bleed within two week prior randomization ( e.g. , gastrointestinal ( GI ) bleeding , intracranial hemorrhage ) 8 . Pregnant lactate woman 9 . Patients history immunemediated neurological disorder multiple sclerosis , GuillainBarré inflammatory CNS/PNS disorder 10 . Clinically significant ascites define require ≥ 1 paracentesis every 2 week 11 . Major surgery , define surgical procedure involve general anesthesia significant incision ( i.e. , large require placement central venous access , percutaneous feed tube , biopsy ) , within 28 day prior randomization anticipate surgery study period 12 . Prior history receive immune modulators include , limited , antiCTLA4 , antiPD1 , antiPDL1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>